Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
Brian Kelley
Advertisement
Brian Kelley is vice president, bioprocess development at Genentech, Inc.
Articles by Brian Kelley
Advertisement
Latest Updated Articles
Purification Strategies to Process 5 g/L Titers of Monoclonal AntibodiesPublished: March 2nd 2009 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Data Quality, Not Regulation, Is the True Barrier to AI in Biologics
2
RNAnalytics CPHI Interview, Part Two: Nanoparticle Case Studies and Response to US mRNA Pullback
3
Strategic Shifts for Speed, Resilience, and Long-Term Sustainability in Biomanufacturing
4
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
5
